Showing results (681-690 of 712) with videos related to

Sort By:
Pageof 72
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 6, 2024
Response Rate and Molecular Correlates to Encorafenib and Binimetinib in BRAF-V600E Mutant High-Grade GliomaKarisa C Schreck, Roy E Strowd, Louis B Nabors, et al.
Nature|May 9, 2000
TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune diseaseJ A Gross, J Johnston, S Mudri, et al.
Neuro-Oncology|April 4, 2017
Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomasMatthias Holdhoff, Xiaobu Ye, Jeffrey G Supko, et al.
Neuro-Oncology Advances|July 24, 2025
Phase I study of NT-I7, a long-acting interleukin-7, in severe treatment-related lymphopenia following standard radiation and temozolomide for high-grade gliomaJian L Campian, Stuart A Grossman, Angela Shaulov Kask, et al.
Neuro-Oncology Advances|October 7, 2024
Lisavanbulin (BAL101553), a novel microtubule inhibitor, plus radiation in patients with newly diagnosed, MGMT promoter unmethylated glioblastomaMatthias Holdhoff, Xiaobu Ye, Roy E Strowd, et al.
Nature Cell Biology|June 27, 2018
Mutant GNAS drives pancreatic tumourigenesis by inducing PKA-mediated SIK suppression and reprogramming lipid metabolismKrushna C Patra, Yasutaka Kato, Yusuke Mizukami, et al.
AJNR. American Journal of Neuroradiology|May 30, 2026
Tumor Growth Rate (TGR) Analysis Predicts Survival in a Multicenter Phase II Study of the PARP Inhibitor Pamiparib (BGB-290) with Temozolomide in Recurrent IDH-Mutant Gliomas (ABTC-1801)Benjamin M Ellingson, Timothy F Cloughesy, Xiaobu Ye, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 1, 2016
Repeatability of <sup>18</sup>F-FLT PET in a Multicenter Study of Patients with High-Grade GliomaMartin A Lodge, Matthias Holdhoff, Jeffrey P Leal, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 29, 2004
A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant settingE Antonio Chiocca, Khalid M Abbed, Stephen Tatter, et al.
Magnetic Resonance Imaging|June 15, 2023
CEST2022: Amide proton transfer-weighted MRI improves the diagnostic performance of multiparametric non-contrast-enhanced MRI techniques in patients with post-treatment high-grade gliomasQianqi Huang, Jingpu Wu, Nhat Le, et al.
Pageof 72